Vimarsana
Biggest News Aggregation in the World

Page 20 - Active Ingredients News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Active Ingredients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Active Ingredients Today - Breaking & Trending Today

Analysts Offer Predictions for Dr. Reddy's Laboratories Limited's Q3 2024 Earnings (NYSE:RDY) - Vimarsana News

Analysts Offer Predictions for Dr. Reddy's Laboratories Limited's Q3 2024 Earnings (NYSE:RDY)

Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) – Equities research analysts at Zacks Research lifted their Q3 2024 earnings per share (EPS) estimates for shares of Dr. Reddy’s Laboratories in a research report issued on Tuesday, July 25th. Zacks Research analyst E. Bagri now expects that the company will earn $0.77 per share for […]

6 Top hair growth oils for healthy hair - Vimarsana News

6 Top hair growth oils for healthy hair

Discover the Top hair growth oils for healthy, luscious hair. Learn about key ingredients, usage tips, and FAQs. Achieve your hair goals naturally!

Dr Reddy's Q1 Results: Net profit rises 18% to Rs 1,402 crore, beats estimates - Vimarsana News

Dr Reddy's Q1 Results: Net profit rises 18% to Rs 1,402 crore, beats estimates

The Street has estimated a net profit of Rs 944.1 crore for the April-June quarter

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded at StockNews.com - Vimarsana News

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded at StockNews.com

StockNews.com upgraded shares of Dr. Reddy’s Laboratories (NYSE:RDY – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday. A number of other brokerages also recently issued reports on RDY. Barclays lifted their price target on Dr. Reddy’s Laboratories from $67.00 to $70.00 in a report […]

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded at StockNews.com - Vimarsana News

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded at StockNews.com

StockNews.com upgraded shares of Dr. Reddy’s Laboratories (NYSE:RDY – Free Report) from a buy rating to a strong-buy rating in a report issued on Friday. RDY has been the topic of a number of other research reports. Barclays upped their price target on shares of Dr. Reddy’s Laboratories from $67.00 to $70.00 in a research […]

Source: wkrb13.com